Related Experiment Video

Updated: Aug 24, 2026

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

Future directions in the treatment of Alzheimer's disease

Roger Bullock1

  • 1Kingshill Research Centre, Victoria Hospital, Swindon, UK. roger.bullock@kingshill-research.org

Expert Opinion on Investigational Drugs
|April 23, 2004
PubMed

Insights

Alzheimer's disease (AD) research is exploring new treatments targeting amyloid-beta and tau pathways. Current therapies offer symptomatic relief, but disease-modifying strategies for dementia are still under investigation.

Area of Science:

  • Neurodegenerative disorders
  • Dementia research
  • Neuropathology

Background:

  • Alzheimer's disease (AD) is the leading cause of dementia in the elderly, often co-occurring with cerebrovascular disease.
  • Current treatments, such as acetylcholinesterase inhibitors, provide symptomatic benefits for cognition, function, and behavior.
  • Disease-modifying strategies for AD are actively being sought to address underlying neuropathological changes.

Purpose of the Study:

  • To review current data guiding future research directions in Alzheimer's disease.
  • To highlight emerging therapeutic targets beyond symptomatic treatment.

Main Methods:

  • Review of current scientific literature and research data on Alzheimer's disease.
  • Analysis of evidence supporting different neuropathological targets.

Main Results:

  • Accumulation of amyloid-beta is a key focus for therapeutic intervention along amyloid pathways.
  • Abnormal tau phosphorylation represents another significant and viable target for AD treatment.
  • Emerging research is paving the way for more molecularly targeted treatment approaches.

Conclusions:

  • Future Alzheimer's disease research is increasingly focused on targeting fundamental neuropathological processes.
  • Interventions targeting both amyloid-beta and tau pathways are critical for developing effective disease-modifying therapies.
  • Continued investigation into the molecular basis of AD is essential for advancing treatment strategies.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...